Related Experiment Video
Updated: Mar 23, 2026
Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
Current status of new tuberculosis vaccine in children
Yu Pang1,2, Aihua Zhao3, Chad Cohen4
1a Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University , Beijing , China.
Insights
An effective pediatric tuberculosis vaccine is crucial for global elimination goals. Current Bacillus Calmette-Guérin (BCG) vaccination offers protection against severe TB, but new vaccine candidates require further evaluation for efficacy in children.
Area of Science:
- Pediatrics
- Infectious Diseases
- Vaccinology
Background:
- Pediatric tuberculosis (TB) represents a significant global health challenge, necessitating improved prevention strategies.
- Bacillus Calmette-Guérin (BCG) vaccination provides protection against severe forms of TB in children, but its efficacy against pulmonary TB is variable.
- Despite development of new TB vaccine candidates, clinical trial data, such as for MVA85A, has shown disappointing protective efficacy in infants.
Purpose of the Study:
- To review the current status of pediatric tuberculosis prevention.
- To evaluate the efficacy of existing and novel tuberculosis vaccines in children.
- To explore strategies for optimizing the use of the current BCG vaccine in pediatric populations.
Main Methods:
- Literature review of pediatric tuberculosis epidemiology and vaccine research.
- Analysis of clinical trial data for novel tuberculosis vaccine candidates in infants.
- Assessment of Bacillus Calmette-Guérin (BCG) vaccine effectiveness against different forms of pediatric TB.
Main Results:
- BCG vaccination is effective against severe disseminated TB (meningitis, miliary TB) but shows inconsistent protection against pediatric pulmonary TB.
- New TB vaccine candidates have demonstrated promising preclinical safety and immunogenicity but have not yet surpassed BCG's clinical efficacy.
- Clinical trials for new pediatric TB vaccines, like MVA85A, have yielded disappointing results regarding protective efficacy.
Conclusions:
- No vaccine currently available is clinically superior to BCG for preventing pediatric tuberculosis.
- Further research is needed to develop more effective TB vaccines for children.
- Optimizing the current BCG vaccination strategy may be essential for maximizing protection in children until superior vaccines are available.
Abstract:
Pediatric tuberculosis contributes significantly to the burden of TB disease worldwide. In order to achieve the goal of eliminating TB by 2050, an effective TB vaccine is urgently needed to prevent TB transmission in children. BCG vaccination can protect children from the severe types of TB such as TB meningitis and miliary TB, while its efficacy against pediatric pulmonary TB ranged from no protection to very high protection. In recent decades, multiple new vaccine candidates have been developed, and shown encouraging safety and immunogenicity in the preclinical experiments. However, the limited data on protective efficacy in infants evaluated by clinical trials has been disappointing, an example being MVA85A. To date, no vaccine has been shown to be clinically safer and more effective than the presently licensed BCG vaccine. Hence, before a new vaccine is developed with more promising efficacy, we must reconsider how to better use the current BCG vaccine to maximize its effectiveness in children.
Related Concept Videos
01:26Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:31Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
01:28Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:51Vaccinations